The adenomatous polyposis coli (APC) tumor suppressor is a nucleocytoplasmic protein. The nuclear accumulation of APC was recently found to vary depending on cell density, suggesting that putative APC function(s) in the nucleus is controlled by the establishment of cell contacts. We report here that the density-dependent redistribution of APC between nucleus and cytoplasm prevails in 6/6 thyroid and colorectal carcinoma cell lines. Moreover, mutated APC lacking known nuclear localization sequences had the similar distribution pattern as the fulllength protein. APC invariably accumulated in the nuclei of Ki-67 expressing cells, but was largely cytoplasmic when cell cycle exit was induced by serum starvation or at high cell density. APC colocalized with b-catenin in the nucleus only in one cell line (SW480). Also, APC maintained a predominantly nuclear position in early confluent states when cytoplasmic b-catenin was recruited to newly formed adherens-like junctions. The results indicate that nuclear targeting of APC is driven by cell cycle entry rather than altered cell-cell contact. The ability of C-terminally truncated APC to accumulate in the nucleus suggests that nuclear import signals other than NLS1 APC and NLS2 APC are functionally important. Residual function(s) of N-terminal APC fragments in tumor cells carrying APC mutations might be beneficial to tumor growth and survival.
Introduction
Germline mutation of the adenomatous polyposis coli (APC) gene is a hallmark of the familial adenomatous polyposis (FAP) syndrome Nishisho et al., 1991; Fearnhead et al., 2001 ). This condition is characterized by the development of hundreds to thousands of colorectal polyps, which inevitably develop into carcinomas. Somatic mutations of APC are also common in sporadic colorectal tumors (Miyoshi et al., 1992) . The majority of these mutations localizes to a central portion of the APC gene, which is known as the mutation cluster region (MCR) (Miyoshi et al., 1992; Rowan et al., 2000) and give rise to Cterminal deletion of the protein product. The tumor suppressor function of full-length APC is attributed to its role in the regulation of b-catenin turnover; APC binds to and targets b-catenin for proteasomal degradation (Rubinfeld et al., 1993; Su et al., 1993; Munemitsu et al., 1995) . If b-catenin is not degraded due to truncating mutations in APC or mutations in b-catenin itself Rubinfeld et al., 1997) , accumulated b-catenin can translocate to the cell nucleus and activate target genes like c-myc (He et al., 1998) , c-jun and fra-1 (Mann et al., 1999) in an uncontrolled manner that is potentially oncogenic.
APC is a large multidomain protein with several interaction partners, implying functions in a broad range of biological processes apart from b-catenin degradation (Fearnhead et al., 2001) . By competing with E-cadherin for its interaction with b-catenin, APC might influence the stability of the adherens junction (Hulsken et al., 1994) . In Drosophila, mutational inactivation of APC results in displacement of the bcatenin homolog Armadillo from the adhesive zones of the plasma membrane (Hamada and Bienz, 2002) . Immunofluorescence studies on mammalian cells also suggest that APC influences the subcellular distribution of b-catenin (Senda et al., 1996; Rosin-Arbesfeld et al., 2000) . However, it is unclear whether cell-cell adhesion reciprocally influences the localization and potentially the function of APC. Several lines of evidence suggest that APC also participates in the regulation of cell proliferation. The ability of APC to bind to microtubuli (Munemitsu et al., 1994; Smith et al., 1994; Nathke et al., 1996) and the centrosome-binding protein EB1 (Su et al., 1995) provides a means by which APC regulates chromosome segregation during mitosis (Fodde et al., 2001a; Kaplan et al., 2001) . APC binds to the B56a regulatory subunit of protein phosphatase 2A (PP2A) (Seeling et al., 1999) and to casein kinase 2 (CK2) (Homma et al., 2002) , which both are important regulators of cell growth. Overexpression of APC inhibits G0 to S progression in tumor cells lacking normal APC (Baeg et al., 1995) .
Recently, APC has been characterized as a nuclear shuttling protein (Rosin-Arbesfeld et al., 2000) . APC immunoreactivity is observed in the nuclei of different cell types (Neufeld and White, 1997) , and both nuclear localization sequences (NLS1 APC and NLS2 APC ) Cterminally of the MCR (Zhang et al., 2000) and nuclear export sequence (NES) motifs in the extreme Nterminus of the protein (Henderson, 2000; Neufeld et al., 2000a) have been identified. More centrally located NESs have also been identified in the vicinity of the MCR (Rosin-Arbesfeld et al., 2000) . However, the functional role of APC in the nucleus is still almost unknown and previously reported observations are partly contradicting. For example, nuclear APC has been found to sequester b-catenin and promote its nuclear export (Henderson, 2000; Neufeld et al., 2000b; Rosin-Arbesfeld et al., 2000) . On the other hand, b-catenin translocation between cytoplasm and nucleus can occur independently of APC (Fagotto et al., 1998; Eleftheriou et al., 2001; Wiechens and Fagotto, 2001) . In MDCK epithelial cells, the nucleocytoplasmic distribution of APC was recently found to vary depending on cell density (Zhang et al., 2001) ; nuclear accumulation of APC was seen in subconfluent cells, whereas superconfluent cultures, presumed to have entered G0, showed no such accumulation. A different conclusion was reached by Brocardo et al. (2001) who suggested that APC acts as a sensor for cell adhesion and moves to the nucleus when cell-cell contacts are disrupted, suggesting that putative nuclear function(s) of APC might be regulated by events taking place at the cell surface. Yet, it is unclear if such nucleocytoplasmic shuttling is impaired when APC is mutated in tumor cells, and if this is of any significance to the tumor phenotype.
In this study we investigated the nuclear localization of APC in malignant tumor cells carrying either normal or mutated APC. The subcellular distribution of APC was studied by immunofluorescence in established cell lines from colorectal carcinoma and thyroid carcinoma, the latter constituting a rare extracolonic manifestation of the FAP syndrome (Cetta et al., 1998) . It is demonstrated that both full-length and truncated APC lacking NLS1 APC , NLS2 APC and all known DNA binding motifs accumulate in tumor cell nuclei in a fashion related to cell proliferation and that this occurs independently of b-catenin cotranslocation. Conversely, the switch from a predominantly nuclear to cytoplasmic APC distribution mainly in confluent cells is related to cell cycle exit and growth arrest and not a direct consequence of the establishment of cell-cell contacts. Altogether, the data indicate that the structural elements that are instrumental for a regulated targeting of APC to the nucleus are not lost in tumor cells regardless of the presence of truncating mutations within the MCR.
Results

Mutation analysis of the APC gene in tumor cell lines
In this study we investigated a panel of widely used anaplastic thyroid carcinoma cell lines for APC protein localization. Since mutations of the APC gene have been reported to occur in thyroid neoplasms (Cetta et al., 1998) , it was important to determine the APC genotype. Screening of APC exons 1-15 by PTT identified no mutations in four of the cell lines (HTh7, HTh74, SW1736 and C643). KAT-4 showed two aberrant protein truncation test (PTT) fragments within exon 15 (Figure 1a) . Direct DNA sequencing (data not shown) revealed that KAT-4 carried a nonsense mutation nt2557G4T, leading to an immediate stop codon Glu853Stop and the insertion nt4666insA, leading to a stop at codon 1557 (nt4671-4673). Further PTT analysis of the region between amino acids 654 and 1700 failed to detect any wild-type fragments, indicating that the two mutations reside on separate alleles. This combination Taking into account hitherto characterized nuclear import motifs, the present data indicate that both NLS1 APC and NLS2 APC are deleted in APC in the KAT-4 cell line (Figure 1c) . However, the protein product of one allele is expected to contain the most N-terminal DNA-binding S(T)PXX motif cluster between amino acids 1360 and 1383 (Deka et al., 1999) (Figure 1c ). As one objective of this work was to study if deletion of hitherto known nuclear import and DNA binding sequences affects the nuclear localization of endogenous APC in tumor cells, we searched for a cell line that expressed APC lacking all these domains. SW480 colon carcinoma cells, carrying only one APC allele that is mutated within the MCR , met this requirement. PTT spanning the entire coding region (Figure 1a ) and direct sequencing (data not shown) confirmed the APC mutation in SW480 to be nt4012C4T producing a stop at codon 1338 ( Figure 1c ). Western blotting confirmed that full-length APC and truncated proteins of the expected sized were expressed in the investigated cell lines (Figure 1b ).
Localization of normal and truncated APC in tumor cell lines
The subcellular localization of endogenous APC in subconfluent (low density) and confluent (high density) tumor cells was investigated by indirect immunofluorescence and confocal microscopy using a polyclonal antiserum against human APC previously demonstrated to be specific for full length and truncated APC (Mogensen et al., 2002) . The images in Figures 2 and 3 were obtained using the affinity-purified anti-APC. Since identical results could be reproduced with crude antiserum this was used in subsequent experiments. As exemplified for C643 in Figure 2a -c, all thyroid carcinoma cell lines that expressed full-length APC had similar APC distribution pattern. In subconfluent cells, 2-3 days after plating, nearly all nuclei showed strong APC immunoreactivity, whereas the cytoplasm was weakly stained (Figure 2a) . Also, nuclear accumulation of APC was evident in most cells early after confluency (Figure 2b ). In contrast, when cells became superconfluent and densely packed, the nuclear localization of APC largely disappeared (Figure 2c) . A density- Figure 1) . It is noteworthy, however, that dispersed KAT-4 cells not adhering to neighboring cells were frequently negative for APC in the nucleus (Figure 2d ). The cytoplasmic APC staining was mostly finely granular and diffusely distributed around the nucleus. In migrating cells with full-length APC, the immunoreactivity was accumulated at leading edges ( Figure 2a , f), similar to previous observations of APC binding to microtubuli (Nathke et al., 1996) .
The finding that a mutant APC lacking NLS1 APC and NLS2 APC entered the nucleus in a regulated fashion suggested the existence of additional, functionally relevant import signals. To further investigate this possibility, we analysed the distribution of APC in SW480 cells that expressed a more N-terminally truncated protein (see Figure 1c) . Immunostaining confirmed the difference in nucleocytoplasmic distribution of APC between subconfluent and confluent cells also in this cell line (Figure 3a, b) . A closer examination of SW480 colonies revealed that peripheral cells facing bare areas of the culture dish displayed the most prominent nuclear accumulation of APC (Figure 3c ). In a transitional zone towards the colony center, in which the cells became more compacted, some nuclei showed intermediate staining intensity for APC (Figure 3c ). Occasionally, APC was concentrated in the nucleus of crowded SW480 cells that were completely surrounded by neighbors lacking nuclear APC (see Figure 4g ).
Localization of APC in proliferating and growth-arrested cells
The growth rates of the tumor cell lines in subconfluent or confluent states are probably different due to more or less crowding of cells. To investigate if APC translocation to the nucleus might be related to proliferation, cells were stained for the Ki-67 antigen known to be expressed in the nucleus throughout the cell cycle, but lacking in G0 (Gerdes et al., 1984) . Most cells in subconfluent, rapidly growing cultures were Ki-67 positive (data not shown). In confluent cultures, the expression of Ki-67 was lost but to a variable extent among the cell lines. As illustrated by double staining of C643 (Figure 4a-c) , (Figure 4d -f) and SW480 (Figure 4g-i) , APC positive nuclei always showed a strong Ki-67 immunoreactivity that decorated the outer portion of the nucleoli. In contrast, Ki-67 was only weakly or not at all expressed in cells lacking nuclear APC; when detected in such cells Ki-67 had a strictly perinuclear or more diffuse cytoplasmic distribution (Figure 4e, f) .
To investigate if the nuclear exclusion of APC could be experimentally induced, serum starvation experiments were performed. Since the cell cycle distribution of tumor cell lines was not consistently affected by short-term serum starvation, we instead used the The corresponding cell fractions that were negative for nuclear APC were 1% and 35%, respectively, in high and low serum conditions (Figure 5a , b, bottom panel).
Nuclear localization of truncated APC and cell cycle progression
Factors directly involved in cell cycle checkpoint mechanisms are known to transiently enter the nucleus during cell cycle progression. Zhang et al. (2001) have shown that full-length APC is constantly expressed in the nucleus throughout the cell cycle. To test if this accounted also for mutated APC in tumor cells, we performed cell cycle analysis by flow cytometry on SW480. In accord with the Ki-67 expression data, the majority of SW480 cells cultured to confluency were found in G0/G1 (Figure 6a ). When cells were replated at low density and further cultured for 24 h, the number of cells in S and G2/M was markedly increased (Figure 6a) . Moreover, the nuclei of these cells were invariably positive for APC. The effect of cell cycle inhibitors, acting at different stages of the cell cycle, on the nucleocytoplasmic distribution of APC was then examined. Before passage, incubation of confluent cells with l-mimosine or apigenin during the last 12 h before passage had no effect on the cell cycle profile, and APC maintained a predominantly cytoplasmic localization (data not shown). After replating, subconfluent cells showed a typical accumulation of G0/G1 cells after mimosine treatment and a G2/M block when exposed to apigenin (Figure 6b) . However, the number of cells expressing nuclear APC was the same regardless of treatment (98 and 99%, respectively, in mimosine-and apigenin-treated cultures).
Comparison of APC and b-catenin subcellullar distribution
As many previous studies indicate an involvement of APC in b-catenin-dependent processes, it was of interest showed a nucleocytoplasmic distribution that was very similar to that of APC: at low cell density nearly all nuclei were strongly labeled (Figure 7a ; see also double immunostaining for b-catenin and APC in Figure 8a ), whereas in crowded cells b-catenin was largely confined to cell-cell contacts and absent in the nucleus (Figure 7b ). However, in the outer portions of SW480 colonies, b-catenin had largely disappeared from the nuclei except in the most peripheral cells (Figure 7c ), whereas some of the b-catenin negative nuclei still showed strong or intermediate APC staining (Figure 7d ). The different localization was more obvious in the other tumor cell lines, for example, b-catenin did not at all accumulate in the nuclei of dispersed KAT-4 cells that mostly were positive for APC (Figure 8b ). Double immunostaining further demonstrated that APC maintained a nuclear localization in newly confluent C643 cells also after that b-catenin was recruited to the plasma membrane and adherens-like junctions were established ( Figure 8c ). To rule out the possibility that differences between the cell lines might be due to genomic aberrations in b-catenin itself, mutational analysis of b-catenin was performed. No mutations of b-catenin exon 3, which is known to contain major mutation hot spots (Rubinfeld et al., 1997) , could be detected in any of the thyroid carcinoma cell lines included in the present study (data not shown). SW480 has previously been demonstrated not to carry any b-catenin mutation (Ilyas et al., 1997) .
Discussion
APC is the second tumor suppressor after p53 that has been identified as a nucleocytoplasmic shuttling protein (Henderson, 2000; Neufeld et al., 2000a; Rosin-Arbesfeld et al., 2000) . Putative functions of nuclear APC is an area of intense research (Bienz, 2002; Henderson and Fagotto, 2002) . In this work, we demonstrate that both wild-type and mutated APC expressed in thyroid and colorectal carcinoma cell lines accumulate in the nucleus in proliferating cells, but not after exit from the cell cycle, for example, at high cell density. The exclusion of APC from the nucleus does not correlate with the establishment of close cell-cell contacts. Moreover, nuclear transport of APC in tumor cells occurs independently of b-catenin translocation to the nucleus or plasma membrane. Most of the work elucidating protein domains that determine the nuclear targeting of APC has been obtained using exogenous and overexpressed APC mutants. Two monopartite nuclear localization signals are mapped to codons 1767-1772 (NLS1 APC ) and 2040-2053 (NLS2 APC ) (Zhang et al., 2000) , and CK2 and PKA phosphorylation sites near NLS2 APC constitute potential regulators of nuclear import (Zhang et al., 2000) . Two nuclear export sequences, spanning codons 63-83 (NES1 APC ) and 161-179 (NES2 APC ), are located in the N-terminus (Henderson, 2000; Neufeld et al., 2000a) . Additionally, more centrally located NES sequences have been identified, originally in Drosophila APC (Rosin-Arbesfeld et al., 2000) . In the present study, the SW480 colon carcinoma cell line expressing only one APC allele with a truncating mutation at codon 1338  confirmed in this study) showed a very strong nuclear APC immunoreactivity at subconfluent growth, as previously observed (Rosin-Arbesfeld et al., 2000) . Similar findings were obtained in KAT-4 thyroid carcinoma cells in which PTT analysis and direct sequencing revealed two APC mutations predicting stop codons at positions 853 and 1557. These findings suggest the existence of yet another more N-terminally located During the preparation of this manuscript, a report on the nuclear localization of various truncated APC constructs was published (Galea et al., 2001) , demonstrating that the N-terminal ARM domain facilitates the nuclear import of APC in the absence of NLS1 APC and NLS2 APC . The present findings support and extend this notion to account also for endogenously mutated APC in a tumor cell context. Recently, it was shown in the nontransformed MDCK epithelial cell line that the nucleocytoplasmic distribution of full-length APC is altered at high cell density when cells cease to grow (Zhang et al., 2001 ). The present findings indicate that in tumor cells also truncated APC lacking the C-terminal half display a similar density-dependent nuclear localization. In fact, the nuclear staining in subconfluent cells was very strong and the reduction of nuclear APC at high tumor cell density was more pronounced than that previously reported for confluent MDCK cells (Zhang et al., 2001) . The density-dependent changes were basically the same for wild-type and mutated APC in the different carcinoma cell lines examined. However, there may be some differences between the nuclear targeting of APC in normal versus tumor cells. In the work by Zhang et al. (2001) , NLS2 APC was found sufficient to confer the nuclear targeting of APC in low-density cells. Moreover, the activity was positively and negatively controlled by, respectively, CK2 and PKA phosphorylation sites located close to NLS2 APC . In view of the fact that these domains are missing in the truncated APC expressed in SW480 and KAT-4, the N-terminal portion of APC likely contains all information required to enter the nucleus in a regulated manner in tumor cells.
Previous studies on the subcellular localization of endogenous APC in tumor cells are few and have yielded different results (Smith et al., 1993; Neufeld and White, 1997; Rosin-Arbesfeld et al., 2000) . At first, the initial findings in the present work suggested that nuclear import of APC is reduced or even blocked when cell-cell contact is established at high tumor cell density. It has also been suggested that disrupted intercellular adhesion, as when cells are replated, may elicit a signal that allows APC to target the nucleus (Brocardo et al., 2001 ). However, a closer examination indicates that gain or loss of cell-cell contact is not obligatory to induce nuclear entry and exit of APC. For example, dispersed KAT-4 cells with no or only sparse connections to neighboring cells were either strongly positive or negative for nuclear APC. Conversely, the formation of adherens-like junctions, as indicated by lateralization of b-catenin along the entire cell perimeter, preceded the nuclear exclusion of APC most notably in the C643 cell line. Instead, the main factor determining the nuclear targeting of APC seemed to be whether the cells were proliferating or not. Specifically, Ki-67, known to be present in any phase of the cell cycle, but not in G0, always coexisted with APC in the nucleus. The nuclear localization of Ki-67 and APC was more abundant in low-density cultures due to their higher proliferation rate. However, such cell profiles were also encountered to a large extent in confluent states reflecting the aberrant growth regulation of the tumor cells. Altogether, these findings indicate that APC does not primarily act as a sensor of altered cell-cell contact, as previously suggested (Brocardo et al., 2001) , but rather responds to cell cycle entry. The fact that all cell lines eventually ceased to proliferate at high density indicated that the tumor cells must be subordinated at least some of the mechanisms that govern contact inhibition of growth. In that sense, the nuclear exclusion of APC may be indirectly linked to cell-cell contact.
Nuclear APC is envisaged a regulatory role in gene expression by sequestering b-catenin and thereby counteracting b-catenin-mediated transactivation of target genes (Henderson, 2000; Neufeld et al., 2000b) . APC has also been suggested to serve as a chaperone that carries b-catenin out of the nucleus for cytoplasmic degradation (Henderson, 2000; Neufeld et al., 2000b) . However, we found no colocalization of b-catenin and APC in the nucleus except in one of the investigated cell lines (SW480). In fact, double immunostaining showed that b-catenin redistributed from nucleus to cytoplasm in newly confluent SW480 cells, while APC was still accumulated in the nucleus. That b-catenin can exit the nucleus independently of the CRM1 export pathways without piggy-backing on APC has previously been suggested Wiechens and Fagotto, 2001) . Also, the present findings argue against the notion that mutant APC might trap b-catenin in the nucleus (Rosin-Arbesfeld et al., 2000) . As we found that regulated nucleocytoplasmic shuttling of APC was not disturbed, accumulation of nuclear b-catenin is therefore more probably a result of impaired degradation in these cells. So what is the nuclear function of APC in dispersed, proliferating cells if b-catenin is not involved? Some previous works suggest participation of APC in cell cycle control by, for example, inhibiting G0/G1 to S progression (Baeg et al., 1995) . Other observations infer a role of APC in blocking the cell cycle by interaction with hDLG (Ishidate et al., 2000) . However, we and Zhang et al. (2001) found that inhibitors of cell cycle progression did not influence the nuclear accumulation of APC. Moreover, the ability of truncated APC lacking the hDLG-binding domain to translocate between nucleus and cytoplasm depending on cell density was not different from that of full-length APC. However, there are other possibilities that nuclear APC might influence growth. The N-terminal portion of APC contains functionally important binding sites to PP2A and CK2 (Seeling et al., 1999; Homma et al., 2002) that are not deleted in most APC mutations including those presently studied. PP2A and CK2 are being increasingly recognized not only as important growth regulators but also as antiapoptotic factors in both normal and tumor cells (Schonthal, 2001; Ahmed et al., 2002) . Speculatively, interactions of APC with PP2A and CK2 during nuclear transport or inside the nucleus might be crucial to mechanisms of importance to tumor cell survival.
In summary, we show here that mutated forms of APC endogenously expressed in colorectal and thyroid carcinoma cell lines are translocated to the nucleus in a density-dependent fashion similar to that recently reported for full-length APC in normal epithelial cells (Zhang et al., 2001) . This property of APC resides in the N-terminal portion of the protein, thereby also encompassing mutant forms lacking NLS1 APC and NLS2 APC . Since biallelic loss of APC is a rare event in tumor development (Rowan et al., 2000) , a selective pressure for the retention of some N-terminal functions of APC in tumor cells has been proposed (Rowan et al., 2000; Sieber et al., 2000; Fodde et al., 2001b) . In view of the present findings that both wild-type and truncated APC accumulate only in the nucleus of proliferating cells throughout the cell cycle, we suggest that an involvement of APC in nuclear growth control mechanism(s) might be one such function.
Materials and methods
Cell culture
Cells were cultured in a humidified atmosphere, 5% CO 2 , at 371C. Anaplastic thyroid carcinoma cell lines (HTh7, HTh74, SW1736 and C643) and MDCK cells were grown in Eagle's minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS). The KAT-4 thyroid carcinoma cell line and the SW480 colon carcinoma cell line were cultured in RPMI 1640 with 10% FBS. All culture reagents were from Gibco (Paisley, UK). Cells were seeded at low or high density and used for experiments at subconfluent or confluent states.
Mutation analysis
Genomic DNA and total RNA were extracted from cultured cell lines using the Wizard Genomic DNA purification kit (Promega, Leiden, The Netherlands) and the RNeasy midi kit (Quiagen, Hilden, Germany), according to the manufacturers' instructions. The entire coding region of the APC gene was screened for mutations using a PTT comprising coupled in vitro transcription/translation of PCR products containing a T7 promotor sequence and an in-frame translational start signal. In order to analyse exons 1-14, 5 mg total RNA was reversely transcribed in a 20 ml reaction buffer using random hexamer priming and Superscript II Reverse Transcriptase (Life Technologies, Ta¨by, Sweden) according to the manufacturer's protocol. Exons 1-14 were analysed in two overlapping fragments containing codon 1-473 and 351-752 and also in one continuous fragment containing codon 1-752 (Prosser et al., 1994) . Exon 15 was analysed in four overlapping fragments containing codons 654-1246 654- , 989-1700 654- , 1595 654- -2337 654- and 2101 654- -2843 654- , respectively (van der Luijt et al., 1997 . PTT reactions were performed with the TNT T7 Quick coupled Transcription/Translation System (Promega) followed by separation of the synthesized protein fragments by electrophoresis on an 8-16% SDS-polyacrylamide gel (Bio-Rad, Sundbyberg, Sweden). Proteins were visualized by autoradiography. The presence of chain-terminating mutations were verified by DNA sequencing using BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Stockholm, Sweden) on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems).
For mutation analysis of b-catenin, PCR was performed for exon 3 using the primers F217 (5 0 -ATTTGATGGAGTTG-GACATGGC-3 0 ) and R427(5 0 -TGAGTGA-AGGACTGA-GAAAATCCC-3 0 ). For single-strand conformational polymorphism analysis, PCR products were subjected to electrophoresis on a nondenaturing, 10% polyacrylamide gel and stained with SYBR Green II (Molecular Probes, Leiden, The Netherlands). For direct DNA sequencing, PCR products were purified using a commercial kit (Qiagen) and sequenced with the Thermo sequenase radiolabeled terminator cycle sequencing kit (Amersham, Uppsala, Sweden).
Western blot analysis
Cells cultured on 35 mm Petri dishes were solubilized in a lysis buffer consisting of 50 mm Tris-HCl pH 7.4, 150 mm NaCl, 1%NP-40, 1% deoxycholate, 0.1% SDS and a mixture of protease inhibitors: 5 mg/ml each of leupeptin and aprotinin (Sigma, St Louis, MO, USA) and 0.4 mm 4-(2-aminoethyl)-benzenesulfonyl fluoride (Pefabloc; Roche, Basel, Switzerland). The protein concentration was determined with the Micro BCAt protein assay kit according to the manufacturer's instructions (Pierce, Rockford, IL, USA). The samples were diluted to equal concentrations in SDS sample buffer and subjected to SDS-polyacrylamide gel electrophoresis using 4-15% gradient gels (Bio-Rad). Proteins were transferred to nitrocellulose in 380 mm glycine, 50 mm Tris and 0.02% SDS at 30 V for 15 h. Filters were blocked in a buffer consisting of 5% fat-free milk in TBS-Tween (20 mm Tris pH 7.6, 137 mm NaCl, 0.1% Tween-20) and then incubated with affinity-purified anti-APC antiserum (Nathke et al., 1996) at 1.3 mg/ml and secondary horseradish peroxidase-conjugated anti-rabbit antibody (Dako, Glostrup, Denmark) for 1 h each. Antibody incubations were followed by washings 6 Â 5 min in TBSTween. The immunolabeled proteins were detected by enhanced chemiluminescence (ECL; Amersham).
Immunofluorescence
Cells cultured on chamber slides (Nunc, Naperville, IL, USA) were fixed in 4% paraformaldehyde in 0.1 m sodium cacodylate, pH 7.2, for 20 min at room temperature and following two rinses in phosphate-buffered saline (PBS) permeabilized with 0.1% Triton X-100 in PBS for 5 min. After three additional washes in PBS, cells were incubated with avidinbiotin blocking reagents (Vector, Burlingame, CA, USA) for 2 Â 10 min and with blocking buffer consisting of 5% fat-free milk, 0.1% gelatin and 7.5% sucrose in PBS for 5 min. For single immunofluorescence, the cells were incubated in sequence with primary antibodies for 1 h, biotin-conjugated secondary antibodies (Amersham) for 30 min and fluoresceinisothiocyanate (FITC)-conjugated streptavidin (Amersham) for 30 min. Immunolabeled cells were counterstained with DAPI (Sigma) to detect cell nuclei. APC was detected using a rabbit polyclonal antiserum raised against human APC (anti-M APC, kindly provided by Dr I Na¨thke; see Nathke et al., 1996) . Other primary antibodies were against the C-terminus of human b-catenin (clone 14, mouse monoclonal IgG; BD Transduction Laboratories, Lexington, KY, USA) and human Ki-67 (Mib-1, mouse monoclonal IgG; Dako). For double immunofluorescence, cells were first stained for b-catenin or Ki-67, as described above, and then incubated with anti-APC that was detected with Rhodamine Red TM -X-conjugated antirabbit IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA). In negative controls, primary antibodies were omitted. The slides were mounted with Vectashield (Vector) and examined in a Nikon Microphot FXA epifluorescence microscope equipped with a QLC100 confocal laser scanning module (VisiTech International, Sunderland, UK). Images were captured on a digital camera and further processed using the Image Pro Plust software (Media Cybernetics, Silver Spring, MD, USA).
